Bristol Obtains Japan Approval for Baraclude, Treatment for Chronic Hepatitis B Patients.Tokyo, Japan, Aug 3, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Bristol-Myers Squibb Japan announced on July 26 that its Baraclude - generic name generic name n. 1. The official nonproprietary name of a drug, under which it is licensed and identified by the manufacturer. 2. : entecavir - had been certifiied by Japan's Health, Labor and Welfare Ministry. Baraclude is an anti-viral action drug for treatment of chronic hepatitis Chronic hepatitis Long lasting inflammation of the liver due to viruses or other causes. Mentioned in: Tube Compression of the Esophagus and Stomach chronic hepatitis B virus infection in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases or histologically active disease. The drug has proven an effective inhibitor of virus replication and has indicated improvements in the increase of alanine aminotransferase alanine aminotransferase /al·a·nine ami·no·trans·fer·ase/ (ah-me?no-trans´fer-as) alanine transaminase. alanine aminotransferase n. Abbr. ALT See SGPT. (ALT) and overall liver health. Baraclude has shown much more benefit over Lamivudine, based on the clinical trials in 5 continents worldwide. the medication has already been approved in 2005 by the Food and Drug Administration in the US, as well as in countries worldwide. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion